- Home
- NLSP vs CANF Comparison
NLSP vs CANF Comparison
Compare NLSP & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- CANF
- Stock Information
- Founded
- NLSP 2015
- CANF 1994
- Country
- NLSP Switzerland
- CANF Israel
- Employees
- NLSP N/A
- CANF N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- NLSP Health Care
- CANF Health Care
- Exchange
- NLSP Nasdaq
- CANF Nasdaq
- Market Cap
- NLSP 12.4M
- CANF 13.5M
- IPO Year
- NLSP 2021
- CANF N/A
- Fundamental
- Price
- NLSP $2.13
- CANF $1.03
- Analyst Decision
- NLSP
- CANF Strong Buy
- Analyst Count
- NLSP 0
- CANF 2
- Target Price
- NLSP N/A
- CANF $14.00
- AVG Volume (30 Days)
- NLSP 268.4K
- CANF 141.2K
- Earning Date
- NLSP 07-22-2025
- CANF 08-29-2025
- Dividend Yield
- NLSP N/A
- CANF N/A
- EPS Growth
- NLSP N/A
- CANF N/A
- EPS
- NLSP N/A
- CANF N/A
- Revenue
- NLSP N/A
- CANF $674,000.00
- Revenue This Year
- NLSP N/A
- CANF $461.72
- Revenue Next Year
- NLSP N/A
- CANF N/A
- P/E Ratio
- NLSP N/A
- CANF N/A
- Revenue Growth
- NLSP N/A
- CANF N/A
- 52 Week Low
- NLSP $1.30
- CANF $0.98
- 52 Week High
- NLSP $15.59
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- NLSP 43.58
- CANF 41.84
- Support Level
- NLSP $2.20
- CANF $1.00
- Resistance Level
- NLSP $2.33
- CANF $1.05
- Average True Range (ATR)
- NLSP 0.25
- CANF 0.03
- MACD
- NLSP -0.07
- CANF 0.00
- Stochastic Oscillator
- NLSP 6.86
- CANF 40.00
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).